Welcome to our dedicated page for Evofem Bioscienc SEC filings (Ticker: EVFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evofem Biosciences, Inc. (EVFM) SEC filings page on Stock Titan brings together the company’s public reports and regulatory disclosures from the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and special meeting proxy statements, and other materials that describe Evofem’s business, capital structure, and key corporate events.
In its SEC filings, Evofem outlines its focus on commercializing PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis. The definitive proxy statement filed on October 29, 2025, for example, discusses the company’s mission in women’s sexual and reproductive health, its strategy to grow net product sales, cost-reduction initiatives, and international licensing arrangements in the Middle East and North Africa.
Recent 8-K filings provide details on specific material events. An October 20, 2025 Form 8-K describes the termination of Evofem’s amended and restated merger agreement with Aditxt, Inc. after stockholders did not approve the proposed transaction, while a November 26, 2025 Form 8-K reports stockholder approval of an amendment to the certificate of incorporation authorizing a reverse stock split within a specified range. Another 8-K dated January 12, 2026 notes that Evofem has made a corporate slide presentation available to investors.
Through Stock Titan, users can access these filings as they are made available on EDGAR and use AI-powered tools to quickly identify key topics such as product strategy, licensing agreements, reverse stock split authorization, and other governance matters. This page is a starting point for reviewing Evofem’s official disclosures, including proxy statements, 8-K current reports, and other SEC documents associated with the EVFM ticker.
Evofem Biosciences (EVFM) terminated its merger agreement with Aditxt effective October 20, 2025, after stockholders did not approve the transaction. The company exercised its contractual right to terminate based on the merger’s outside date and the failure to obtain Company Shareholder Approval. All related ancillary agreements ended concurrently, except for the existing non‑disclosure agreement. No consideration was paid in connection with the termination.
At the October 20 special meeting, quorum was reached with 100,494,436 votes represented out of 256,360,511 eligible votes. Proposal 1 to approve the merger received 93,239,872 votes for, 7,208,466 against, and 46,097 withheld, and was not approved. Proposal 2, authorizing potential adjournment, passed with 97,435,999 for, 2,840,322 against, and 218,115 withheld.
The company cautioned that termination could affect operations and relationships and referenced risks including potential costs and obligations described in its risk disclosures.
Evofem Biosciences (EVFM) entered a third amendment to its Securities Purchase Agreement with Adjuvant on October 13, 2025. The amendment updates when the related convertible notes become payable in full to the earlier of six months after the Effective Date, at Adjuvant’s election upon a Change of Control, or the date of any acceleration under Section 8.
The notes may not be prepaid before the date that is six months after the Effective Date without Adjuvant’s prior written consent. This sets a defined near‑term timeline for potential repayment while limiting early prepayment.